MSF comments on WHA's clinical trial resolution
The United Kingdom and Argentina are tabling a resolution on clinical trials at the upcoming 75th World Health Assembly. While the zero draft of the resolution articulates important features to be incorporated in clinical trial policies and practices, MSF believes the resolution can be strengthened to better serve public health needs. To this end, we recommend the following actions to member states:
- Ensure that the scope of the resolution is applicable to all clinical trials related to all medical technologies and not only to vaccines
- Include full transparency requirements, such as sharing of protocols, timely publication of data and public disclosure of research and development (R&D) costs, including the costs of clinical trials, particularly when public funds are assigned to the research
- Take into consideration the need for diversity of populations enrolled in clinical trials, as appropriate
- Safeguard unhindered access to comparator drugs, diagnostics and vaccines needed for research and/or bioequivalence purposes
- Embed access and benefit-sharing principles and conditions in clinical trial management and governance
In this regard, we are hosting a roundtable meeting to discuss this topic at length tomorrow. See attached for more details and here is the link to register: https://us06web.zoom.us/meeting/register/tZMrf-2grDsoHN1UJmdtrAqL7mCTLYgaNcxr
MSF’s detailed comments on this leaked resolution can be accessed here: https://msfaccess.org/msf-comments-clinical-trial-resolution-75th-world-health-assembly
Please feel free to connect in case you have any questions.
Best
Shailly
Shailly Gupta
+41-79 203 13 02
